Hib-DTP-hepatitis-B vaccine - LG Life Sciences

Drug Profile

Hib-DTP-hepatitis-B vaccine - LG Life Sciences

Alternative Names: DTwP-HB/Hib; DTwP-HepB-Hib (recon.); Euforvac-Hib; LBVF0101

Latest Information Update: 08 Oct 2015

Price : $50

At a glance

  • Originator LG Life Sciences
  • Class
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Registered Diphtheria; Haemophilus infections; Hepatitis B; Pertussis; Tetanus

Most Recent Events

  • 28 Aug 2015 Phase-III clinical trials in Diphtheria (In children, In infants, Prevention) in China (IM)
  • 28 Aug 2015 Phase-III clinical trials in Haemophilus infections (In children, In infants, Prevention) in China (IM)
  • 28 Aug 2015 Phase-III clinical trials in Hepatitis B (In children, In infants, Prevention) in China (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top